| abstract |
An antibody of a targeting TACSTD2, an Antibody Drug Conjugate (ADC) molecule, and a general ADC linker technology with good druggability. Specifically, disclosed are an optimized ADC molecule of the targeting TACSTD2, preparation method therefor, pharmaceutical use thereof, and effect thereof on inhibiting or treating tumors. Experimental results indicate that the ADC molecule has an anti-tumor effect better than congeneric molecules. Meanwhile, also disclosed is an optimized method for performing specific PEG modification on the ADC linker containing vc (valine-citrulline). |